Jinwon Life Sciences Advances Domestic Clinical Development of Oral Treatment to Suppress Severe COVID-19

[Asia Economy Reporter Jang Hyowon] GeneOne Life Science announced on the 24th that it will promote domestic clinical development of GLS-1027, an oral therapeutic agent that suppresses severe lung disease after COVID-19 infection, which has received Phase 2 clinical approval from the US FDA.

A company official stated, "With the recent increase in domestic confirmed cases and the limitations and difficulties in dedicated treatment for severe patients, the need for a proactive therapeutic agent that suppresses progression to severe disease after confirmation is increasing. GLS-1027, an oral low-molecular drug that inhibits cytokines, which are inflammation-inducing substances, has shown effectiveness in preventing severe lung disease caused by COVID-19. Therefore, it is expected to play a role as a proactive therapeutic agent, and rapid clinical development will be conducted domestically."

Park Younggeun, CEO of GeneOne Life Science, said, "We are currently preparing to apply for Phase 2 clinical trial approval from the Ministry of Food and Drug Safety for GLS-1027. Unlike vaccines, it can receive approval for therapeutic use as well as rapid clinical results. Compared to other COVID-19 treatments, it has no immunosuppressive side effects in infected patients and is convenient to administer orally, making treatment possible even during self-isolation of confirmed patients."

This content was produced with the assistance of AI translation services.